CA2366038A1

CA2366038A1 - Treating a variety of pathological conditions, including spasticity and convulsions, by effecting modulation of cns activity with isovaleramide, isovaleric acid, or a related compound

Treating a variety of pathological conditions, including spasticity and convulsions, by effecting modulation of cns activity with isovaleramide, isovaleric acid, or a related compound Download PDF

Info

Publication number: CA2366038A1
Authority: CA; Canada
Prior art keywords: compound; isovaleramide; pathology; dimethylisovaleramide; isovaleric acid
Prior art date: 1999-03-01
Legal status : Abandoned

Application number

CA002366038A

Other languages

English (en)

French (fr)

Inventor

Linda D. Artman

Manuel Balandrin

Robert L. Smith

Current Assignee

Shire NPS Pharmaceuticals Inc

Original Assignee

Individual

Priority date

1999-03-01

Filing date

2000-03-01

Publication date

2000-09-08

2000-03-01 Application filed by Individual filed Critical Individual

2000-09-08 Publication of CA2366038A1 publication Critical patent/CA2366038A1/en

Status Abandoned legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 95
SANOUVWGPVYVAV-UHFFFAOYSA-N isovaleramide Chemical compound CC(C)CC(N)=O SANOUVWGPVYVAV-UHFFFAOYSA-N 0.000 title claims abstract description 95
206010010904 Convulsion Diseases 0.000 title claims abstract description 85
230000000694 effects Effects 0.000 title claims abstract description 72
208000008238 Muscle Spasticity Diseases 0.000 title claims abstract description 51
GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 title claims abstract description 51
208000018198 spasticity Diseases 0.000 title claims abstract description 51
GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 title claims abstract description 48
XYHKNCXZYYTLRG-UHFFFAOYSA-N 1h-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 title claims abstract description 45
230000036461 convulsion Effects 0.000 title claims abstract description 19
230000001575 pathological effect Effects 0.000 title abstract description 9
239000000284 extract Substances 0.000 claims abstract description 12
230000001668 ameliorated effect Effects 0.000 claims abstract description 7
238000000034 method Methods 0.000 claims description 60
230000007170 pathology Effects 0.000 claims description 31
150000001408 amides Chemical class 0.000 claims description 21
208000019022 Mood disease Diseases 0.000 claims description 16
208000001431 Psychomotor Agitation Diseases 0.000 claims description 16
208000011580 syndromic disease Diseases 0.000 claims description 16
206010038743 Restlessness Diseases 0.000 claims description 15
150000003839 salts Chemical class 0.000 claims description 14
238000001727 in vivo Methods 0.000 claims description 13
150000002148 esters Chemical class 0.000 claims description 11
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
201000009032 substance abuse Diseases 0.000 claims description 10
206010019233 Headaches Diseases 0.000 claims description 9
235000019788 craving Nutrition 0.000 claims description 9
244000025221 Humulus lupulus Species 0.000 claims description 8
235000008694 Humulus lupulus Nutrition 0.000 claims description 8
230000002490 cerebral effect Effects 0.000 claims description 8
208000004296 neuralgia Diseases 0.000 claims description 8
208000021722 neuropathic pain Diseases 0.000 claims description 8
231100000736 substance abuse Toxicity 0.000 claims description 8
208000011117 substance-related disease Diseases 0.000 claims description 8
208000016285 Movement disease Diseases 0.000 claims description 7
231100000869 headache Toxicity 0.000 claims description 7
LINZZISWCNKFEM-UHFFFAOYSA-N 3,3-dimethylbutanamide Chemical compound CC(C)(C)CC(N)=O LINZZISWCNKFEM-UHFFFAOYSA-N 0.000 claims description 6
OVPLZYJGTGDFNB-UHFFFAOYSA-N propan-2-yl carbamate Chemical compound CC(C)OC(N)=O OVPLZYJGTGDFNB-UHFFFAOYSA-N 0.000 claims description 6
WXVBAUOIPSBUQU-UHFFFAOYSA-N 2,2,3-trimethylbutanamide Chemical compound CC(C)C(C)(C)C(N)=O WXVBAUOIPSBUQU-UHFFFAOYSA-N 0.000 claims description 5
RUBTXJHNGCJRGT-UHFFFAOYSA-N 2,2,3-trimethylpentanamide Chemical compound CCC(C)C(C)(C)C(N)=O RUBTXJHNGCJRGT-UHFFFAOYSA-N 0.000 claims description 5
ZGGBHZGLQCFMOU-UHFFFAOYSA-N 2,3,3-trimethylbutanamide Chemical compound NC(=O)C(C)C(C)(C)C ZGGBHZGLQCFMOU-UHFFFAOYSA-N 0.000 claims description 5
HRBAJVQRJUTNMM-UHFFFAOYSA-N 2,3-dimethylpentanamide Chemical compound CCC(C)C(C)C(N)=O HRBAJVQRJUTNMM-UHFFFAOYSA-N 0.000 claims description 5
WQPHBKCACJYXGG-UHFFFAOYSA-N 2-hydroxy-3-methylbutanamide Chemical compound CC(C)C(O)C(N)=O WQPHBKCACJYXGG-UHFFFAOYSA-N 0.000 claims description 5
BRUZQRBVNRKLJG-UHFFFAOYSA-N 2-methylpropyl carbamate Chemical compound CC(C)COC(N)=O BRUZQRBVNRKLJG-UHFFFAOYSA-N 0.000 claims description 5
GTEXJHWORUNPND-UHFFFAOYSA-N 3,3-dimethylpentanamide Chemical compound CCC(C)(C)CC(N)=O GTEXJHWORUNPND-UHFFFAOYSA-N 0.000 claims description 5
QHNHAWNULKRVMJ-UHFFFAOYSA-N 3-hydroxy-3-methylbutanamide Chemical compound CC(C)(O)CC(N)=O QHNHAWNULKRVMJ-UHFFFAOYSA-N 0.000 claims description 5
SIMLCFANWCDGAF-UHFFFAOYSA-N 3-methylpentanamide Chemical compound CCC(C)CC(N)=O SIMLCFANWCDGAF-UHFFFAOYSA-N 0.000 claims description 5
BHCVWPVYBPQCLV-UHFFFAOYSA-N 4-hydroxy-3,3-dimethylbutanamide Chemical compound OCC(C)(C)CC(N)=O BHCVWPVYBPQCLV-UHFFFAOYSA-N 0.000 claims description 5
DRIVYJITCPWHBB-UHFFFAOYSA-N 4-hydroxy-3-methylbutanamide Chemical compound OCC(C)CC(N)=O DRIVYJITCPWHBB-UHFFFAOYSA-N 0.000 claims description 5
244000071378 Viburnum opulus Species 0.000 claims description 5
ULCGRQKYGXIIIF-UHFFFAOYSA-N propan-2-yl sulfamate Chemical compound CC(C)OS(N)(=O)=O ULCGRQKYGXIIIF-UHFFFAOYSA-N 0.000 claims description 5
WQBCZTUSIWRNDW-UHFFFAOYSA-N 2,3-dimethylbutanamide Chemical compound CC(C)C(C)C(N)=O WQBCZTUSIWRNDW-UHFFFAOYSA-N 0.000 claims description 4
IWEYZXWPWNBRLG-UHFFFAOYSA-N 2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(N)(=O)=O IWEYZXWPWNBRLG-UHFFFAOYSA-N 0.000 claims description 4
OREDTCNNUVRHNM-UHFFFAOYSA-N 2-methylpropyl sulfamate Chemical compound CC(C)COS(N)(=O)=O OREDTCNNUVRHNM-UHFFFAOYSA-N 0.000 claims description 4
235000013483 European cranberry bush Nutrition 0.000 claims description 4
241000792902 Valerianaceae Species 0.000 claims description 4
240000002715 Viburnum prunifolium Species 0.000 claims description 4
235000013248 Viburnum prunifolium Nutrition 0.000 claims description 4
230000004112 neuroprotection Effects 0.000 claims description 3
UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical group C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 claims 2
101100167062 Caenorhabditis elegans chch-3 gene Chemical group 0.000 claims 2
IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical group C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 claims 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
238000011282 treatment Methods 0.000 abstract description 32
244000126014 Valeriana officinalis Species 0.000 abstract description 23
235000013832 Valeriana officinalis Nutrition 0.000 abstract description 21
235000016788 valerian Nutrition 0.000 abstract description 21
238000002360 preparation method Methods 0.000 abstract description 17
239000000203 mixture Substances 0.000 abstract description 13
230000000144 pharmacologic effect Effects 0.000 abstract description 9
230000001624 sedative effect Effects 0.000 abstract description 4
231100000065 noncytotoxic Toxicity 0.000 abstract 1
230000002020 noncytotoxic effect Effects 0.000 abstract 1
241000700159 Rattus Species 0.000 description 48
239000001961 anticonvulsive agent Substances 0.000 description 46
208000024891 symptom Diseases 0.000 description 33
241001465754 Metazoa Species 0.000 description 27
230000001773 anti-convulsant effect Effects 0.000 description 26
241000699670 Mus sp. Species 0.000 description 25
229960003965 antiepileptics Drugs 0.000 description 25
239000003814 drug Substances 0.000 description 25
-1 isovaleryl glycinamide Chemical compound 0.000 description 23
238000012360 testing method Methods 0.000 description 23
210000003169 central nervous system Anatomy 0.000 description 22
229940079593 drug Drugs 0.000 description 22
206010015037 epilepsy Diseases 0.000 description 22
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 21
230000001535 kindling effect Effects 0.000 description 20
239000003795 chemical substances by application Substances 0.000 description 19
239000008194 pharmaceutical composition Substances 0.000 description 19
229940102566 valproate Drugs 0.000 description 19
239000000126 substance Substances 0.000 description 18
208000007101 Muscle Cramp Diseases 0.000 description 17
208000005392 Spasm Diseases 0.000 description 17
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 16
241000699666 Mus <mouse, genus> Species 0.000 description 16
230000001684 chronic effect Effects 0.000 description 16
238000007912 intraperitoneal administration Methods 0.000 description 15
230000004044 response Effects 0.000 description 15
230000001154 acute effect Effects 0.000 description 14
238000010171 animal model Methods 0.000 description 14
230000011514 reflex Effects 0.000 description 14
229940125681 anticonvulsant agent Drugs 0.000 description 13
235000019441 ethanol Nutrition 0.000 description 13
PPXUHEORWJQRHJ-UHFFFAOYSA-N ethyl isovalerate Chemical compound CCOC(=O)CC(C)C PPXUHEORWJQRHJ-UHFFFAOYSA-N 0.000 description 13
229960003692 gamma aminobutyric acid Drugs 0.000 description 13
208000014674 injury Diseases 0.000 description 13
210000003205 muscle Anatomy 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
241000282414 Homo sapiens Species 0.000 description 11
238000011161 development Methods 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 11
238000002560 therapeutic procedure Methods 0.000 description 11
KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 10
208000006011 Stroke Diseases 0.000 description 10
239000002253 acid Substances 0.000 description 10
229960000794 baclofen Drugs 0.000 description 10
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 10
230000003247 decreasing effect Effects 0.000 description 10
230000001988 toxicity Effects 0.000 description 10
231100000419 toxicity Toxicity 0.000 description 10
206010039897 Sedation Diseases 0.000 description 9
208000035475 disorder Diseases 0.000 description 9
230000036280 sedation Effects 0.000 description 9
210000002435 tendon Anatomy 0.000 description 9
208000024255 Audiogenic seizures Diseases 0.000 description 8
241000557626 Corvus corax Species 0.000 description 8
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
239000004471 Glycine Substances 0.000 description 8
241000282412 Homo Species 0.000 description 8
230000003542 behavioural effect Effects 0.000 description 8
230000006735 deficit Effects 0.000 description 8
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 8
230000009467 reduction Effects 0.000 description 8
238000010825 rotarod performance test Methods 0.000 description 8
230000001148 spastic effect Effects 0.000 description 8
230000008733 trauma Effects 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
208000010428 Muscle Weakness Diseases 0.000 description 7
206010028372 Muscular weakness Diseases 0.000 description 7
150000001298 alcohols Chemical class 0.000 description 7
229940049706 benzodiazepine Drugs 0.000 description 7
230000006378 damage Effects 0.000 description 7
229960003529 diazepam Drugs 0.000 description 7
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
206010009346 Clonus Diseases 0.000 description 6
208000002193 Pain Diseases 0.000 description 6
206010043275 Teratogenicity Diseases 0.000 description 6
229940124575 antispasmodic agent Drugs 0.000 description 6
150000001557 benzodiazepines Chemical class 0.000 description 6
230000037396 body weight Effects 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
230000000324 neuroprotective effect Effects 0.000 description 6
230000036407 pain Effects 0.000 description 6
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
210000000278 spinal cord Anatomy 0.000 description 6
231100000211 teratogenicity Toxicity 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
241000196324 Embryophyta Species 0.000 description 5
206010019851 Hepatotoxicity Diseases 0.000 description 5
208000012902 Nervous system disease Diseases 0.000 description 5
208000025966 Neurological disease Diseases 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
210000004727 amygdala Anatomy 0.000 description 5
230000002059 anti-epileptogenic effect Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
229960003920 cocaine Drugs 0.000 description 5
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 5
231100000304 hepatotoxicity Toxicity 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
201000006417 multiple sclerosis Diseases 0.000 description 5
239000006186 oral dosage form Substances 0.000 description 5
230000028527 righting reflex Effects 0.000 description 5
239000003826 tablet Substances 0.000 description 5
MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 5
208000000187 Abnormal Reflex Diseases 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
206010002091 Anaesthesia Diseases 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 4
206010021118 Hypotonia Diseases 0.000 description 4
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
208000019695 Migraine disease Diseases 0.000 description 4
206010033799 Paralysis Diseases 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
206010044565 Tremor Diseases 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000037005 anaesthesia Effects 0.000 description 4
230000006399 behavior Effects 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
230000003111 delayed effect Effects 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
230000001815 facial effect Effects 0.000 description 4
235000013305 food Nutrition 0.000 description 4
230000003371 gabaergic effect Effects 0.000 description 4
210000003128 head Anatomy 0.000 description 4
230000007686 hepatotoxicity Effects 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
230000035859 hyperreflexia Effects 0.000 description 4
206010020745 hyperreflexia Diseases 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
230000003902 lesion Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
229910052744 lithium Inorganic materials 0.000 description 4
210000003141 lower extremity Anatomy 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 4
208000015122 neurodegenerative disease Diseases 0.000 description 4
239000007787 solid Substances 0.000 description 4
208000005809 status epilepticus Diseases 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000003390 teratogenic effect Effects 0.000 description 4
230000001256 tonic effect Effects 0.000 description 4
229960000604 valproic acid Drugs 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
206010001497 Agitation Diseases 0.000 description 3
208000020925 Bipolar disease Diseases 0.000 description 3
206010017577 Gait disturbance Diseases 0.000 description 3
206010019196 Head injury Diseases 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
206010026749 Mania Diseases 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
208000005793 Restless legs syndrome Diseases 0.000 description 3
238000000692 Student's t-test Methods 0.000 description 3
239000005862 Whey Substances 0.000 description 3
102000007544 Whey Proteins Human genes 0.000 description 3
108010046377 Whey Proteins Proteins 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000009471 action Effects 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
230000000202 analgesic effect Effects 0.000 description 3
239000006286 aqueous extract Substances 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
150000004657 carbamic acid derivatives Chemical class 0.000 description 3
230000002920 convulsive effect Effects 0.000 description 3
238000002651 drug therapy Methods 0.000 description 3
230000002964 excitative effect Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000003194 forelimb Anatomy 0.000 description 3
230000006870 function Effects 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000009539 inhibitory neurotransmission Effects 0.000 description 3
HZGMZSCMYSGJTL-UHFFFAOYSA-N isovaleric acid triglyceride Natural products CC(C)CC(=O)OCC(OC(=O)CC(C)C)COC(=O)CC(C)C HZGMZSCMYSGJTL-UHFFFAOYSA-N 0.000 description 3
206010027599 migraine Diseases 0.000 description 3
230000007659 motor function Effects 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
235000019645 odor Nutrition 0.000 description 3
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000011591 potassium Substances 0.000 description 3
230000004224 protection Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
229960004889 salicylic acid Drugs 0.000 description 3
239000000932 sedative agent Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
241000894007 species Species 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 3
229940124530 sulfonamide Drugs 0.000 description 3
150000003456 sulfonamides Chemical class 0.000 description 3
231100000378 teratogenic Toxicity 0.000 description 3
231100000027 toxicology Toxicity 0.000 description 3
BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 3
229960005318 vigabatrin Drugs 0.000 description 3
PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 3
238000005303 weighing Methods 0.000 description 3
DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
HJRDWZDREUWADS-UHFFFAOYSA-N 3-methylbutanoyl 2-hydroxybenzoate Chemical compound CC(C)CC(=O)OC(=O)C1=CC=CC=C1O HJRDWZDREUWADS-UHFFFAOYSA-N 0.000 description 2
PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 2
206010000117 Abnormal behaviour Diseases 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
206010003591 Ataxia Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
208000033001 Complex partial seizures Diseases 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
208000002877 Epileptic Syndromes Diseases 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
229940122459 Glutamate antagonist Drugs 0.000 description 2
102000011714 Glycine Receptors Human genes 0.000 description 2
108010076533 Glycine Receptors Proteins 0.000 description 2
206010048533 Hypervigilance Diseases 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
108090000862 Ion Channels Proteins 0.000 description 2
102000004310 Ion Channels Human genes 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
244000062730 Melissa officinalis Species 0.000 description 2
235000010654 Melissa officinalis Nutrition 0.000 description 2
OQAGVSWESNCJJT-UHFFFAOYSA-N Methyl 3-methylbutanoate Chemical compound COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 2
208000007379 Muscle Hypotonia Diseases 0.000 description 2
241000790228 Nardostachys jatamansi Species 0.000 description 2
208000033952 Paralysis flaccid Diseases 0.000 description 2
206010033864 Paranoia Diseases 0.000 description 2
208000027099 Paranoid disease Diseases 0.000 description 2
208000037158 Partial Epilepsies Diseases 0.000 description 2
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
206010040703 Simple partial seizures Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000004809 Teflon Substances 0.000 description 2
229920006362 Teflon® Polymers 0.000 description 2
BDIAUFOIMFAIPU-KVJIRVJXSA-N Valtratum Chemical compound C([C@]12[C@@H]3C(C(=CO[C@H]3OC(=O)CC(C)C)COC(C)=O)=C[C@@H]1OC(=O)CC(C)C)O2 BDIAUFOIMFAIPU-KVJIRVJXSA-N 0.000 description 2
235000019013 Viburnum opulus Nutrition 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
RKCHCKMAQPJXBM-UHFFFAOYSA-N ammonium isovalerate Chemical compound N.CC(C)CC(O)=O RKCHCKMAQPJXBM-UHFFFAOYSA-N 0.000 description 2
230000036592 analgesia Effects 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
230000002921 anti-spasmodic effect Effects 0.000 description 2
230000000949 anxiolytic effect Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000003874 central nervous system depressant Substances 0.000 description 2
206010008129 cerebral palsy Diseases 0.000 description 2
230000008859 change Effects 0.000 description 2
239000012707 chemical precursor Substances 0.000 description 2
239000000812 cholinergic antagonist Substances 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
235000008504 concentrate Nutrition 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000003179 convulsant agent Substances 0.000 description 2
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
239000002662 enteric coated tablet Substances 0.000 description 2
230000001037 epileptic effect Effects 0.000 description 2
RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
210000003414 extremity Anatomy 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
208000028331 flaccid paralysis Diseases 0.000 description 2
208000017561 flaccidity Diseases 0.000 description 2
208000028316 focal seizure Diseases 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
229960002870 gabapentin Drugs 0.000 description 2
LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
239000007897 gelcap Substances 0.000 description 2
208000028326 generalized seizure Diseases 0.000 description 2
239000011521 glass Substances 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
230000002008 hemorrhagic effect Effects 0.000 description 2
239000000399 hydroalcoholic extract Substances 0.000 description 2
230000002218 hypoglycaemic effect Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 2
229950003188 isovaleryl diethylamide Drugs 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
238000005259 measurement Methods 0.000 description 2
210000002418 meninge Anatomy 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229930003658 monoterpene Natural products 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
239000003176 neuroleptic agent Substances 0.000 description 2
239000004090 neuroprotective agent Substances 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
229960005489 paracetamol Drugs 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
210000001747 pupil Anatomy 0.000 description 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000000384 rearing effect Effects 0.000 description 2
201000005070 reflex epilepsy Diseases 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000035807 sensation Effects 0.000 description 2
235000019615 sensations Nutrition 0.000 description 2
238000000926 separation method Methods 0.000 description 2
229950005143 sitosterol Drugs 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
208000020431 spinal cord injury Diseases 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000005556 structure-activity relationship Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
230000007428 synaptic transmission, GABAergic Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
229940072651 tylenol Drugs 0.000 description 2
DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
229940068146 valepotriate Drugs 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
229960001600 xylazine Drugs 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
GXWUEMSASMVWKO-GNLHUFSQSA-N (4as,6ar,6as,6br,10s,12ar,14br)-10-[(2s,3r,4s,5s)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CCC2C1(C)C)C)(C)CC[C@]1(CCC(C[C@@H]14)(C)C)C(O)=O)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GXWUEMSASMVWKO-GNLHUFSQSA-N 0.000 description 1
ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
MLFLWIBXZIPYEI-UHFFFAOYSA-N 2,2,3-trimethylbutanoic acid Chemical compound CC(C)C(C)(C)C(O)=O MLFLWIBXZIPYEI-UHFFFAOYSA-N 0.000 description 1
JAUKQUVPYOBDNP-UHFFFAOYSA-N 2,2,3-trimethylpentanoic acid Chemical compound CCC(C)C(C)(C)C(O)=O JAUKQUVPYOBDNP-UHFFFAOYSA-N 0.000 description 1
JDEUUKYNTHHAQH-UHFFFAOYSA-N 2,2-dimethylbutanamide Chemical compound CCC(C)(C)C(N)=O JDEUUKYNTHHAQH-UHFFFAOYSA-N 0.000 description 1
VUAXHMVRKOTJKP-UHFFFAOYSA-N 2,2-dimethylbutyric acid Chemical compound CCC(C)(C)C(O)=O VUAXHMVRKOTJKP-UHFFFAOYSA-N 0.000 description 1
ILBXYVICWFMUPR-UHFFFAOYSA-N 2,3,3-trimethylbutanoic acid Chemical compound OC(=O)C(C)C(C)(C)C ILBXYVICWFMUPR-UHFFFAOYSA-N 0.000 description 1
XFOASZQZPWEJAA-UHFFFAOYSA-N 2,3-dimethylbutyric acid Chemical compound CC(C)C(C)C(O)=O XFOASZQZPWEJAA-UHFFFAOYSA-N 0.000 description 1
WGPXFMSGCKHJPH-UHFFFAOYSA-N 2-(3-methylbutanoyloxy)benzoic acid Chemical compound CC(C)CC(=O)OC1=CC=CC=C1C(O)=O WGPXFMSGCKHJPH-UHFFFAOYSA-N 0.000 description 1
CYGPPWVXOWCHJB-UHFFFAOYSA-N 2-Methylbutyl 3-methylbutanoate Chemical compound CCC(C)COC(=O)CC(C)C CYGPPWVXOWCHJB-UHFFFAOYSA-N 0.000 description 1
NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 description 1
MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
RPBPHGSYVPJXKT-UHFFFAOYSA-N 3-bromo-2-phenylmethoxypyridine Chemical compound BrC1=CC=CN=C1OCC1=CC=CC=C1 RPBPHGSYVPJXKT-UHFFFAOYSA-N 0.000 description 1
AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 1
IGIDLTISMCAULB-UHFFFAOYSA-N 3-methylvaleric acid Chemical compound CCC(C)CC(O)=O IGIDLTISMCAULB-UHFFFAOYSA-N 0.000 description 1
239000002999 4 aminobutyrate aminotransferase inhibitor Substances 0.000 description 1
239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
ZGYGEPZZMAXSKH-UHFFFAOYSA-N 4-Hydroxyisovaleric acid Chemical compound OCC(C)CC(O)=O ZGYGEPZZMAXSKH-UHFFFAOYSA-N 0.000 description 1
WLKUATLKPJGHKX-UHFFFAOYSA-N 4-hydroxy-3,3-dimethylbutanoic acid Chemical compound OCC(C)(C)CC(O)=O WLKUATLKPJGHKX-UHFFFAOYSA-N 0.000 description 1
PRUMMFPRJSEJJL-UHFFFAOYSA-N 4-morpholin-4-yl-3-nitroaniline Chemical compound [O-][N+](=O)C1=CC(N)=CC=C1N1CCOCC1 PRUMMFPRJSEJJL-UHFFFAOYSA-N 0.000 description 1
OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
108700023418 Amidases Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
235000014722 Aralia cordata Nutrition 0.000 description 1
244000294554 Aralia racemosa Species 0.000 description 1
235000004446 Aralia racemosa Nutrition 0.000 description 1
241000271566 Aves Species 0.000 description 1
206010048994 Bladder spasm Diseases 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
241000208828 Caprifoliaceae Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical class NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000009132 Catalepsy Diseases 0.000 description 1
206010008120 Cerebral ischaemia Diseases 0.000 description 1
NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
206010008748 Chorea Diseases 0.000 description 1
101150065749 Churc1 gene Proteins 0.000 description 1
208000018652 Closed Head injury Diseases 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
206010010947 Coordination abnormal Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010011985 Decubitus ulcer Diseases 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
PHHROXLDZHUIGO-PNBTUHDLSA-N Didrovaltratum Chemical compound C([C@@]12[C@@H](OC(C)=O)C[C@H]3[C@@H]1[C@H](OC(=O)CC(C)C)OC=C3COC(=O)CC(C)C)O2 PHHROXLDZHUIGO-PNBTUHDLSA-N 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
229920002079 Ellagic acid Polymers 0.000 description 1
241000283086 Equidae Species 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
239000005770 Eugenol Substances 0.000 description 1
208000027776 Extrapyramidal disease Diseases 0.000 description 1
206010015995 Eyelid ptosis Diseases 0.000 description 1
238000000729 Fisher's exact test Methods 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
102000005915 GABA Receptors Human genes 0.000 description 1
108010005551 GABA Receptors Proteins 0.000 description 1
230000009508 GABAergic inhibition Effects 0.000 description 1
244000287680 Garcinia dulcis Species 0.000 description 1
239000005792 Geraniol Substances 0.000 description 1
GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
208000009693 Gingival Hyperplasia Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
KQEOKUJOWVGWDX-UHFFFAOYSA-N Isodihydrovaltrate Natural products CC(C)CC(=O)OC1CC(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 KQEOKUJOWVGWDX-UHFFFAOYSA-N 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
MPYYVGIJHREDBO-UHFFFAOYSA-N Isovaleriansaeure-isobornylester Natural products C1CC2(C)C(OC(=O)CC(C)C)CC1C2(C)C MPYYVGIJHREDBO-UHFFFAOYSA-N 0.000 description 1
VYQSSWZYPCCBRN-UHFFFAOYSA-N Isovaleriansaeure-menthylester Natural products CC(C)CC(=O)OC1CC(C)CCC1C(C)C VYQSSWZYPCCBRN-UHFFFAOYSA-N 0.000 description 1
FOCMOGKCPPTERB-UHFFFAOYSA-N Isovaleriansaeure-trans-cinnamylester Natural products CC(C)CC(=O)OCC=CC1=CC=CC=C1 FOCMOGKCPPTERB-UHFFFAOYSA-N 0.000 description 1
206010023230 Joint stiffness Diseases 0.000 description 1
VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
206010023644 Lacrimation increased Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010658 Lavandula latifolia Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000219823 Medicago Species 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
241000218231 Moraceae Species 0.000 description 1
208000021966 Motor seizure Diseases 0.000 description 1
208000002740 Muscle Rigidity Diseases 0.000 description 1
206010028347 Muscle twitching Diseases 0.000 description 1
206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
241000772415 Neovison vison Species 0.000 description 1
GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
208000007920 Neurogenic Inflammation Diseases 0.000 description 1
206010057852 Nicotine dependence Diseases 0.000 description 1
MMOPREBWKCZVPO-ZIKNSQGESA-N OC(=O)C=CC1=CC=C(O)C=C1.OC(=O)\C=C\C1=CC=C(O)C=C1 Chemical compound OC(=O)C=CC1=CC=C(O)C=C1.OC(=O)\C=C\C1=CC=C(O)C=C1 MMOPREBWKCZVPO-ZIKNSQGESA-N 0.000 description 1
241000906034 Orthops Species 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
206010035039 Piloerection Diseases 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
208000023146 Pre-existing disease Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
102100038239 Protein Churchill Human genes 0.000 description 1
UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
101150054830 S100A6 gene Proteins 0.000 description 1
206010039424 Salivary hypersecretion Diseases 0.000 description 1
206010040108 Serotonin syndrome Diseases 0.000 description 1
206010041415 Spastic paralysis Diseases 0.000 description 1
208000010040 Sprains and Strains Diseases 0.000 description 1
206010042008 Stereotypy Diseases 0.000 description 1
206010072148 Stiff-Person syndrome Diseases 0.000 description 1
238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
231100000288 TD50 Toxicity 0.000 description 1
206010043118 Tardive Dyskinesia Diseases 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
208000031320 Teratogenesis Diseases 0.000 description 1
JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
241000606265 Valeriana jatamansi Species 0.000 description 1
206010047163 Vasospasm Diseases 0.000 description 1
229930003270 Vitamin B Natural products 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
206010047853 Waxy flexibility Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
FOCMOGKCPPTERB-RMKNXTFCSA-N [(e)-3-phenylprop-2-enyl] 3-methylbutanoate Chemical compound CC(C)CC(=O)OC\C=C\C1=CC=CC=C1 FOCMOGKCPPTERB-RMKNXTFCSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
102000005922 amidase Human genes 0.000 description 1
239000003194 amino acid receptor blocking agent Substances 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000003561 anti-manic effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
230000001663 anti-spastic effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
230000037007 arousal Effects 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000011914 asymmetric synthesis Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000003693 atypical antipsychotic agent Substances 0.000 description 1
229940127236 atypical antipsychotics Drugs 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
208000021018 autosomal dominant inheritance Diseases 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
UPURPFNAFBQPON-UHFFFAOYSA-N beta,beta-dimethyl valeric acid Chemical compound CCC(C)(C)CC(O)=O UPURPFNAFBQPON-UHFFFAOYSA-N 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
231100001015 blood dyscrasias Toxicity 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
235000004420 brassicasterol Nutrition 0.000 description 1
OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
235000004883 caffeic acid Nutrition 0.000 description 1
229940074360 caffeic acid Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000000431 campesterol Nutrition 0.000 description 1
SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
239000007894 caplet Substances 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
208000012601 choreatic disease Diseases 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
229960004414 clomethiazole Drugs 0.000 description 1
230000002566 clonic effect Effects 0.000 description 1
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
230000019771 cognition Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000013872 defecation Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
229950005934 didrovaltrate Drugs 0.000 description 1
PVKOJQHHDYMUEI-UHFFFAOYSA-N didrovaltrate Natural products CC(C)CC(=O)COC1=COC(OC(=O)CC(C)C)C2C1CC(OC(=O)C)C23CO3 PVKOJQHHDYMUEI-UHFFFAOYSA-N 0.000 description 1
PHHROXLDZHUIGO-UHFFFAOYSA-N dihydrovaltrate Natural products CC(C)CC(=O)OCC1=COC(OC(=O)CC(C)C)C2C1CC(OC(C)=O)C21CO1 PHHROXLDZHUIGO-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
208000004206 drug-induced akathisia Diseases 0.000 description 1
210000001951 dura mater Anatomy 0.000 description 1
230000000142 dyskinetic effect Effects 0.000 description 1
230000001544 dysphoric effect Effects 0.000 description 1
229960002852 ellagic acid Drugs 0.000 description 1
235000004132 ellagic acid Nutrition 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229960002179 ephedrine Drugs 0.000 description 1
238000010931 ester hydrolysis Methods 0.000 description 1
239000000469 ethanolic extract Substances 0.000 description 1
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
XIGZBCUFFUBWDM-UHFFFAOYSA-N ethyl 2-acetylheptanoate Chemical compound CCCCCC(C(C)=O)C(=O)OCC XIGZBCUFFUBWDM-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229960002217 eugenol Drugs 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000009540 excitatory neurotransmission Effects 0.000 description 1
208000001936 exophthalmos Diseases 0.000 description 1
229940114124 ferulic acid Drugs 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
210000004744 fore-foot Anatomy 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000003445 gaba agent Substances 0.000 description 1
FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
229940074391 gallic acid Drugs 0.000 description 1
235000004515 gallic acid Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
235000021472 generally recognized as safe Nutrition 0.000 description 1
235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229940113087 geraniol Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003825 glutamate receptor antagonist Substances 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000035876 healing Effects 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000018706 hematopoietic system disease Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
231100000334 hepatotoxic Toxicity 0.000 description 1
230000003082 hepatotoxic effect Effects 0.000 description 1
239000012674 herbal formulation Substances 0.000 description 1
241000411851 herbal medicine Species 0.000 description 1
238000009161 herbalism Methods 0.000 description 1
235000008216 herbs Nutrition 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
230000001632 homeopathic effect Effects 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000016290 incoordination Diseases 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
230000003447 ipsilateral effect Effects 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
QZMQDHNCNUGQSO-UHFFFAOYSA-N isovaleryl diethylamide Chemical compound CCN(CC)C(=O)CC(C)C QZMQDHNCNUGQSO-UHFFFAOYSA-N 0.000 description 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
230000004317 lacrimation Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000002684 laminectomy Methods 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229930007744 linalool Natural products 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
238000009136 lithium therapy Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000018883 loss of balance Diseases 0.000 description 1
MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
229930186179 lupulin Natural products 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
239000000401 methanolic extract Substances 0.000 description 1
OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000000897 modulatory effect Effects 0.000 description 1
150000002773 monoterpene derivatives Chemical class 0.000 description 1
230000036651 mood Effects 0.000 description 1
208000005264 motor neuron disease Diseases 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
230000003387 muscular Effects 0.000 description 1
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
231100000243 mutagenic effect Toxicity 0.000 description 1
230000007886 mutagenicity Effects 0.000 description 1
231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
GFWZPTGIVKRQNM-UHFFFAOYSA-N n,3-dimethylbutanamide Chemical compound CNC(=O)CC(C)C GFWZPTGIVKRQNM-UHFFFAOYSA-N 0.000 description 1
LVQDLURAEDSMES-UHFFFAOYSA-N n,n,3-trimethylbutanamide Chemical compound CC(C)CC(=O)N(C)C LVQDLURAEDSMES-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
DUIVBXGYYJPSJX-UHFFFAOYSA-N n-methylpropane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC DUIVBXGYYJPSJX-UHFFFAOYSA-N 0.000 description 1
239000007959 natural flavoring substance Substances 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
230000007971 neurological deficit Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000003961 neuronal insult Effects 0.000 description 1
238000011859 neuroprotective therapy Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
208000027753 pain disease Diseases 0.000 description 1
229940055726 pantothenic acid Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
230000008289 pathophysiological mechanism Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229960000395 phenylpropanolamine Drugs 0.000 description 1
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229940068065 phytosterols Drugs 0.000 description 1
230000005371 pilomotor reflex Effects 0.000 description 1
235000002378 plant sterols Nutrition 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000013641 positive control Substances 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
244000144977 poultry Species 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
IBALRBWGSVJPAP-HEHNFIMWSA-N progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 description 1
229960002752 progabide Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229960003908 pseudoephedrine Drugs 0.000 description 1
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
201000003004 ptosis Diseases 0.000 description 1
235000021251 pulses Nutrition 0.000 description 1
235000008160 pyridoxine Nutrition 0.000 description 1
239000011677 pyridoxine Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
235000005875 quercetin Nutrition 0.000 description 1
229960001285 quercetin Drugs 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
208000026451 salivation Diseases 0.000 description 1
208000022610 schizoaffective disease Diseases 0.000 description 1
238000013077 scoring method Methods 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
229940084026 sodium valproate Drugs 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000002048 spasmolytic effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
229940032091 stigmasterol Drugs 0.000 description 1
235000016831 stigmasterol Nutrition 0.000 description 1
BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical class [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
229940124598 therapeutic candidate Drugs 0.000 description 1
KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
235000019157 thiamine Nutrition 0.000 description 1
229960003495 thiamine Drugs 0.000 description 1
239000011721 thiamine Substances 0.000 description 1
DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
229960000488 tizanidine Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000008791 toxic response Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
229960003732 tyramine Drugs 0.000 description 1
150000003675 ursolic acids Chemical class 0.000 description 1
235000020767 valerian extract Nutrition 0.000 description 1
229940072690 valium Drugs 0.000 description 1
OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 description 1
229960001930 valpromide Drugs 0.000 description 1
229950008559 valtrate Drugs 0.000 description 1
125000002114 valyl group Chemical group 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000003135 vibrissae Anatomy 0.000 description 1
235000019156 vitamin B Nutrition 0.000 description 1
239000011720 vitamin B Substances 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
238000009941 weaving Methods 0.000 description 1
CHETUOSYZGKTOC-UHFFFAOYSA-L zinc;3-methylbutanoate Chemical class [Zn+2].CC(C)CC([O-])=O.CC(C)CC([O-])=O CHETUOSYZGKTOC-UHFFFAOYSA-L 0.000 description 1
QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1